OTC Watch

All stocks / BLGO

BIOLARGO, INC. BLGO

Biolargo (BLGO): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQXCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
BIOLARGO INC
Market tier
OTCQX US
Trading status
Active
Last trade
Nov 16
Website
www.biolargo.com/
Source: Stockwatch, 2026-11-17

News headlines

BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
2026-11-17 08:30 · News Release
BioLargo Targets Growing Industrial PFAS Market with MasterClass at International Water Conference
2026-11-09 08:30 · News Release
BioLargo's BEST Expands Industrial PFAS Treatment Activities Amid Major PFAS Settlements
2026-11-05 08:30 · News Release
BioLargo Announces Launch of barebird.com
2026-11-03 08:30 · News Release
BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption
2026-11-02 08:30 · News Release
BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success
2026-10-28 09:26 · News Release
BioLargo Subsidiary Clyra Medical to Exhibit at SAWC Fall 2026 in Las Vegas
2026-10-13 09:30 · News Release
Gabelli To Host 4th Annual PFAS Symposium
2026-09-16 08:00 · News Release
BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
2026-09-10 09:00 · News Release
BioLargo Townhall and Q2 2026 Earnings Results Webcast and Conference Call on Thursday, September 10th, 2026 - 4:00 PM Eastern Time
2026-09-09 08:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($15,189,000)
What it means

It spends more than it earns

Under strain

The company lost $15.2 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$3,883,000
Net cash used in operating activities
($8,297,000)
What it means

The cash could run out soon

Under strain

It had $3.9 million in the bank and used about $691,417 a month. At that pace the money lasts about 6 months unless it borrows or sells more shares.

The report says
Total assets
$8,311,000
Total liabilities
$6,785,000
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $8.3 million. Its debts and unpaid bills add up to $6.8 million. That is about $0.82 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-12

Estimated float about 299,479,232 shares as of 2026-11-12: 338,443,806 outstanding minus 38,964,574 held by 2 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-05-14
302.8M
2025-08-12
309.0M
2025-11-12
313.8M
2026-03-02
319.8M
2026-04-29
320.9M
2026-05-14
320.9M
2026-08-12
328.7M
2026-11-12
338.4M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-QFORM 10-Q
2026-11-02 8-KFORM 8-K
2026-10-19 DEF 14AFORM DEF 14A
2026-10-02 4FORM 4
2026-10-02 4FORM 4
2026-10-02 4FORM 4
2026-10-02 4FORM 4
2026-10-02 4FORM 4
2026-10-02 4FORM 4
2026-09-14 8-K/AFORM 8-K/A
2026-09-11 8-KFORM 8-K
2026-08-14 10-QFORM 10-Q

Common questions about BLGO

Does BLGO file reports with the SEC?

Yes. Biolargo files with the SEC under company number 0000880242. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many BLGO shares are outstanding?

338,443,806 shares as of 2026-11-12, as reported to the SEC.

Source record

Has BLGO filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Biolargo?

Officers named in its insider filings: Dennis P Calvert (President), Kenneth Reay Code (Chief Science Officer) and Charles K Dargan (Chief Financial Officer).

Source record

Is Biolargo making money?

The company lost $15.2 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record